Posted by Michael Wonder on 10 Apr 2026
Sobi receives Health Canada approval for Empaveli (pegcetacoplan) for the treatment of C3G and primary IC-MPGN
9 April 2026 - Approval supported by Phase 3 52 week VALIANT study demonstrated reduced proteinuria, stabilsed kidney function and C3 deposit clearance.
Swedish Orphan Biovitrum announced today that Health Canada has approved Empaveli (pegcetacoplan), a complement inhibitor, for the treatment of adult and paediatric patients aged 12 years and older with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis to reduce proteinuria.
